RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REPLIGEN CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$176.43+1.01 (+0.58%)
Close on Oct 19, 2026
- Market cap
- $9.99B
- P/E (TTM)
- 205.2
- Dividend yield
- –
Community
Notes and questions about Repligen from other investors
No posts about RGEN yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.